Cytomx Therapeutics (CTMX) Market Summary
- Current Trading Price: USD 2.51
- Price Change (24 h): +2.63 % (ended 05:10 AM Central Europe, Wednesday 21st)
- Shares Outstanding: 217.9 million
- Market Capitalization: USD 496.8 million
- Trading Volume (last 24 h): USD 4.8 million
- Year‑to‑Date Performance: –15.22 % since the end of the previous month
- 200‑Day Simple Moving Average: USD 3.96
- 52‑Week High: USD 8.21 (16 March 2026)
- 52‑Week Low: USD 2.20 (14 October 2026)
Comparative Performance of Peer Stocks (Last 24 h)
| Symbol | Company | Price Change | Current Price (USD) | Market Cap (USD mn) | P/E Ratio |
|---|---|---|---|---|---|
| IRWD | Ironwood | +1.71 % | 3.63 | 592.4 | 4.55 |
| FBIZ | First Business Ser | –1.02 % | 71.00 | 590.1 | 10.72 |
| ZVRA | Zevra Therapeutics | +2.21 % | 10.47 | 590.3 | 10.43 |
| SLDB | Solid Biosciences | +7.05 % | 6.40 | 593.0 | – |
| AVR | Anteris Glo | +2.15 % | 6.29 | 589.8 | – |
Company Overview
Cytomx Therapeutics, Inc. is an oncology‑focused biopharmaceutical company listed on the Nasdaq stock exchange. The company specializes in the development of probody therapeutics for cancer treatment. Cytomx serves pharmaceutical industries primarily in the United States. Key corporate milestones include an initial public offering on 8 October 2015. For detailed information, visit the company’s website at www.cytomx.com .
